NetScientific (GB:EMVC) has released an update. EMV Capital’s portfolio company, PDS Biotechnology, has updated its clinical programs and financial results for the third quarter of 2024, showing a net loss
NetScientific (GB:EMVC) has released an update. EMV Capital’s portfolio company, PDS Biotechnology, has updated its clinical programs and financial results for the third quarter of 2024, showing a net loss
NetScientific (GB:EMVC) has released an update. EMV Capital’s portfolio company, PDS Biotechnology, has announced updates on its clinical programs and financial results for Q3 2024. The biotech firm, which focuses
NetScientific (GB:EMVC) has released an update. EMV Capital plc reports that its CEO, Dr. Ilian Iliev, and Executive Director, Ed Hooper, have collectively acquired 31,335 ordinary shares of the company
NetScientific (GB:EMVC) has released an update. Senior Independent Director of EMV Capital plc, Dr. Jonathan Robinson, has bolstered his stake in the company by purchasing 25,000 ordinary shares through his
NetScientific (GB:EMVC) has released an update. PDS Biotechnology, a portfolio company of EMV Capital plc, reported impressive results from its IMMUNOCERV Phase 2 clinical trial at the ASTRO Annual Meeting